APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioids Agonist Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Opioids Agonist Drugs Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchOpioids Agonist Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioids Agonist Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Opioids Agonist Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioids Agonist Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioids Agonist Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Opioids Agonist Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Opioids Agonist Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Opioids Agonist Drugs market include Janssen Pharmaceuticals, Inc, Sun Pharmaceuticals, Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc, AbbVie Inc., Titan pharmaceuticals, Purdue Pharma and Mallinckrodt Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Opioids Agonist Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioids Agonist Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioids Agonist Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Opioids Agonist Drugs market.

Opioids Agonist Drugs Segment by Company

Janssen Pharmaceuticals, Inc

Sun Pharmaceuticals

Sanofi

Johnson & Johnson Services, Inc.

Pfizer Inc

AbbVie Inc.

Titan pharmaceuticals

Purdue Pharma

Mallinckrodt Pharmaceuticals

Hikma Pharmaceuticals PLC

Grünenthal

Endo Pharmaceuticals Inc.

Egalet Corporation

Boehringer Ingelheim

Allergan, Plc

Opioids Agonist Drugs Segment by Type

Fentanyl

Codeine

Morphine

Methadone

Meperidine

Hydrocodone

Opioids Agonist Drugs Segment by Application

Pain Management

Cough Treatment

Diarrhea Treatment

Opioids Agonist Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Opioids Agonist Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Opioids Agonist Drugs key companies, revenue, market share, and recent developments.

3. To split the Opioids Agonist Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Opioids Agonist Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioids Agonist Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Opioids Agonist Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioids Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Agonist Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioids Agonist Drugs industry.

Chapter 3: Detailed analysis of Opioids Agonist Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Opioids Agonist Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Opioids Agonist Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioids Agonist Drugs Industry Trends Table 2. Opioids Agonist Drugs Industry Drivers Table 3. Opioids Agonist Drugs Industry Opportunities and Challenges Table 4. Opioids Agonist Drugs Industry Restraints Table 5. Global Opioids Agonist Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioids Agonist Drugs Revenue Share by Company (2021-2026) Table 7. Global Opioids Agonist Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Opioids Agonist Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Opioids Agonist Drugs Company, Product Type & Application Table 10. Global Opioids Agonist Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Opioids Agonist Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Fentanyl Table 15. Significant Companies of Codeine Table 16. Significant Companies of Morphine Table 17. Significant Companies of Methadone Table 18. Significant Companies of Meperidine Table 19. Significant Companies of Hydrocodone Table 20. Global Opioids Agonist Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Opioids Agonist Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Opioids Agonist Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Opioids Agonist Drugs Sales Value Share by Type (2021-2026) Table 24. Global Opioids Agonist Drugs Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Pain Management Table 26. Significant Companies of Cough Treatment Table 27. Significant Companies of Diarrhea Treatment Table 28. Global Opioids Agonist Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Opioids Agonist Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Opioids Agonist Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Opioids Agonist Drugs Sales Value Share by Application (2021-2026) Table 32. Global Opioids Agonist Drugs Sales Value Share by Application (2027-2032) Table 33. Global Opioids Agonist Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Opioids Agonist Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Opioids Agonist Drugs Sales Value Share by Region (2021-2026) Table 36. Global Opioids Agonist Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Opioids Agonist Drugs Sales Value Share by Region (2027-2032) Table 38. Global Opioids Agonist Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Opioids Agonist Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Opioids Agonist Drugs Sales Value Market Share by Country (2021-2026) Table 41. Global Opioids Agonist Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Opioids Agonist Drugs Sales Value Market Share by Country (2027-2032) Table 43. Janssen Pharmaceuticals, Inc Company Information Table 44. Janssen Pharmaceuticals, Inc Business Overview Table 45. Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio Table 47. Janssen Pharmaceuticals, Inc Recent Development Table 48. Sun Pharmaceuticals Company Information Table 49. Sun Pharmaceuticals Business Overview Table 50. Sun Pharmaceuticals Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio Table 52. Sun Pharmaceuticals Recent Development Table 53. Sanofi Company Information Table 54. Sanofi Business Overview Table 55. Sanofi Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Sanofi Opioids Agonist Drugs Product Portfolio Table 57. Sanofi Recent Development Table 58. Johnson & Johnson Services, Inc. Company Information Table 59. Johnson & Johnson Services, Inc. Business Overview Table 60. Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio Table 62. Johnson & Johnson Services, Inc. Recent Development Table 63. Pfizer Inc Company Information Table 64. Pfizer Inc Business Overview Table 65. Pfizer Inc Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Inc Opioids Agonist Drugs Product Portfolio Table 67. Pfizer Inc Recent Development Table 68. AbbVie Inc. Company Information Table 69. AbbVie Inc. Business Overview Table 70. AbbVie Inc. Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. AbbVie Inc. Opioids Agonist Drugs Product Portfolio Table 72. AbbVie Inc. Recent Development Table 73. Titan pharmaceuticals Company Information Table 74. Titan pharmaceuticals Business Overview Table 75. Titan pharmaceuticals Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio Table 77. Titan pharmaceuticals Recent Development Table 78. Purdue Pharma Company Information Table 79. Purdue Pharma Business Overview Table 80. Purdue Pharma Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Purdue Pharma Opioids Agonist Drugs Product Portfolio Table 82. Purdue Pharma Recent Development Table 83. Mallinckrodt Pharmaceuticals Company Information Table 84. Mallinckrodt Pharmaceuticals Business Overview Table 85. Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio Table 87. Mallinckrodt Pharmaceuticals Recent Development Table 88. Hikma Pharmaceuticals PLC Company Information Table 89. Hikma Pharmaceuticals PLC Business Overview Table 90. Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio Table 92. Hikma Pharmaceuticals PLC Recent Development Table 93. Grünenthal Company Information Table 94. Grünenthal Business Overview Table 95. Grünenthal Opioids Agonist Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Grünenthal Opioids Agonist Drugs Product Portfolio Table 97. Grünenthal Recent Development Table 98. Endo Pharmaceuticals Inc. Company Information Table 99. Endo Pharmaceuticals Inc. Business Overview Table 100. Endo Pharmaceuticals Inc. Opioids Agonist Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio Table 102. Endo Pharmaceuticals Inc. Recent Development Table 103. Egalet Corporation Company Information Table 104. Egalet Corporation Business Overview Table 105. Egalet Corporation Opioids Agonist Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Egalet Corporation Opioids Agonist Drugs Product Portfolio Table 107. Egalet Corporation Recent Development Table 108. Boehringer Ingelheim Company Information Table 109. Boehringer Ingelheim Business Overview Table 110. Boehringer Ingelheim Opioids Agonist Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio Table 112. Boehringer Ingelheim Recent Development Table 113. Allergan, Plc Company Information Table 114. Allergan, Plc Business Overview Table 115. Allergan, Plc Opioids Agonist Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Allergan, Plc Opioids Agonist Drugs Product Portfolio Table 117. Allergan, Plc Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Opioids Agonist Drugs Product Image Figure 2. Global Opioids Agonist Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioids Agonist Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioids Agonist Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Fentanyl Image Figure 8. Codeine Image Figure 9. Morphine Image Figure 10. Methadone Image Figure 11. Meperidine Image Figure 12. Hydrocodone Image Figure 13. Global Opioids Agonist Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Opioids Agonist Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Opioids Agonist Drugs Sales Value Share by Type (2021-2032) Figure 16. Pain Management Image Figure 17. Cough Treatment Image Figure 18. Diarrhea Treatment Image Figure 19. Global Opioids Agonist Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Opioids Agonist Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Opioids Agonist Drugs Sales Value Share by Application (2021-2032) Figure 22. Global Opioids Agonist Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Opioids Agonist Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Opioids Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. North America Opioids Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Opioids Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Opioids Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Opioids Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Opioids Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Opioids Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. South America Opioids Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Opioids Agonist Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Opioids Agonist Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Opioids Agonist Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Fentanyl
  • Codeine
  • Morphine
  • Methadone
  • Meperidine
  • Hydrocodone
Applications
  • Pain Management
  • Cough Treatment
  • Diarrhea Treatment
Companies covered
  • Janssen Pharmaceuticals, Inc
  • Sun Pharmaceuticals
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc
  • AbbVie Inc.
  • Titan pharmaceuticals
  • Purdue Pharma
  • Mallinckrodt Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Grünenthal
  • Endo Pharmaceuticals Inc.
  • Egalet Corporation
  • Boehringer Ingelheim
  • Allergan, Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Opioids Agonist Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Opioids Agonist Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Opioids Agonist Drugs Market Dynamics
  1. 2.1 Opioids Agonist Drugs Industry Trends
  2. 2.2 Opioids Agonist Drugs Industry Drivers
  3. 2.3 Opioids Agonist Drugs Industry Opportunities and Challenges
  4. 2.4 Opioids Agonist Drugs Industry Restraints
3 Opioids Agonist Drugs Market by Company
  1. 3.1 Global Opioids Agonist Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Opioids Agonist Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Opioids Agonist Drugs Company Ranking (2024-2026)
  4. 3.4 Global Opioids Agonist Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Opioids Agonist Drugs Company Product Type and Application
  6. 3.6 Global Opioids Agonist Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Opioids Agonist Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Opioids Agonist Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Opioids Agonist Drugs Market by Type
  1. 4.1 Opioids Agonist Drugs Type Introduction
  2. 4.1.1 Fentanyl
  3. 4.1.2 Codeine
  4. 4.1.3 Morphine
  5. 4.1.4 Methadone
  6. 4.1.5 Meperidine
  7. 4.1.6 Hydrocodone
  8. 4.2 Global Opioids Agonist Drugs Sales Value by Type
  9. 4.2.1 Global Opioids Agonist Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Opioids Agonist Drugs Sales Value by Type (2021-2032)
  11. 4.2.3 Global Opioids Agonist Drugs Sales Value Share by Type (2021-2032)
5 Opioids Agonist Drugs Market by Application
  1. 5.1 Opioids Agonist Drugs Application Introduction
  2. 5.1.1 Pain Management
  3. 5.1.2 Cough Treatment
  4. 5.1.3 Diarrhea Treatment
  5. 5.2 Global Opioids Agonist Drugs Sales Value by Application
  6. 5.2.1 Global Opioids Agonist Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioids Agonist Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Opioids Agonist Drugs Sales Value Share by Application (2021-2032)
6 Opioids Agonist Drugs Regional Value Analysis
  1. 6.1 Global Opioids Agonist Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioids Agonist Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Opioids Agonist Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Opioids Agonist Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Opioids Agonist Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Opioids Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Opioids Agonist Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Opioids Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Opioids Agonist Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Opioids Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Opioids Agonist Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Opioids Agonist Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Opioids Agonist Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Opioids Agonist Drugs Sales Value Share by Country, 2025 VS 2032
7 Opioids Agonist Drugs Country-level Value Analysis
  1. 7.1 Global Opioids Agonist Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioids Agonist Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Opioids Agonist Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Opioids Agonist Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Opioids Agonist Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Opioids Agonist Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Opioids Agonist Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Pharmaceuticals, Inc
  2. 8.1.1 Janssen Pharmaceuticals, Inc Company Information
  3. 8.1.2 Janssen Pharmaceuticals, Inc Business Overview
  4. 8.1.3 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio
  6. 8.1.5 Janssen Pharmaceuticals, Inc Recent Developments
  7. 8.2 Sun Pharmaceuticals
  8. 8.2.1 Sun Pharmaceuticals Company Information
  9. 8.2.2 Sun Pharmaceuticals Business Overview
  10. 8.2.3 Sun Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Opioids Agonist Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson Services, Inc.
  20. 8.4.1 Johnson & Johnson Services, Inc. Company Information
  21. 8.4.2 Johnson & Johnson Services, Inc. Business Overview
  22. 8.4.3 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Services, Inc. Recent Developments
  25. 8.5 Pfizer Inc
  26. 8.5.1 Pfizer Inc Company Information
  27. 8.5.2 Pfizer Inc Business Overview
  28. 8.5.3 Pfizer Inc Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc Opioids Agonist Drugs Product Portfolio
  30. 8.5.5 Pfizer Inc Recent Developments
  31. 8.6 AbbVie Inc.
  32. 8.6.1 AbbVie Inc. Company Information
  33. 8.6.2 AbbVie Inc. Business Overview
  34. 8.6.3 AbbVie Inc. Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Inc. Opioids Agonist Drugs Product Portfolio
  36. 8.6.5 AbbVie Inc. Recent Developments
  37. 8.7 Titan pharmaceuticals
  38. 8.7.1 Titan pharmaceuticals Company Information
  39. 8.7.2 Titan pharmaceuticals Business Overview
  40. 8.7.3 Titan pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio
  42. 8.7.5 Titan pharmaceuticals Recent Developments
  43. 8.8 Purdue Pharma
  44. 8.8.1 Purdue Pharma Company Information
  45. 8.8.2 Purdue Pharma Business Overview
  46. 8.8.3 Purdue Pharma Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Purdue Pharma Opioids Agonist Drugs Product Portfolio
  48. 8.8.5 Purdue Pharma Recent Developments
  49. 8.9 Mallinckrodt Pharmaceuticals
  50. 8.9.1 Mallinckrodt Pharmaceuticals Company Information
  51. 8.9.2 Mallinckrodt Pharmaceuticals Business Overview
  52. 8.9.3 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio
  54. 8.9.5 Mallinckrodt Pharmaceuticals Recent Developments
  55. 8.10 Hikma Pharmaceuticals PLC
  56. 8.10.1 Hikma Pharmaceuticals PLC Company Information
  57. 8.10.2 Hikma Pharmaceuticals PLC Business Overview
  58. 8.10.3 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio
  60. 8.10.5 Hikma Pharmaceuticals PLC Recent Developments
  61. 8.11 Grünenthal
  62. 8.11.1 Grünenthal Company Information
  63. 8.11.2 Grünenthal Business Overview
  64. 8.11.3 Grünenthal Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Grünenthal Opioids Agonist Drugs Product Portfolio
  66. 8.11.5 Grünenthal Recent Developments
  67. 8.12 Endo Pharmaceuticals Inc.
  68. 8.12.1 Endo Pharmaceuticals Inc. Company Information
  69. 8.12.2 Endo Pharmaceuticals Inc. Business Overview
  70. 8.12.3 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio
  72. 8.12.5 Endo Pharmaceuticals Inc. Recent Developments
  73. 8.13 Egalet Corporation
  74. 8.13.1 Egalet Corporation Company Information
  75. 8.13.2 Egalet Corporation Business Overview
  76. 8.13.3 Egalet Corporation Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Egalet Corporation Opioids Agonist Drugs Product Portfolio
  78. 8.13.5 Egalet Corporation Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 Allergan, Plc
  86. 8.15.1 Allergan, Plc Company Information
  87. 8.15.2 Allergan, Plc Business Overview
  88. 8.15.3 Allergan, Plc Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Allergan, Plc Opioids Agonist Drugs Product Portfolio
  90. 8.15.5 Allergan, Plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst